Effect of PPCI on Diastolic Function & Levels of Galactin-3 in Patients With STEMI

NCT ID: NCT05107076

Last Updated: 2021-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-11-30

Study Completion Date

2023-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* 2D Echocardiography with color Doppler assessment: It will be done within 24 h after PPCI
* Peripheral blood samples were obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level.
* Follow up 2D Doppler echocardiography:

will be repeated at 40 days of the event.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

2D Echocardiography with color Doppler assessment:

It will be done within 24 h after PPCI. Measurements will be as following:

1. Pulsed wave (PW) Doppler will be performed in the apical 4chamber view within a 3 mm sample volume at the tip of the mitral leaflets to obtain mitral inflow velocities to assess LV filling.
2. E (early diastolic)/A (late diastolic) - Using PW Doppler, the peak E and A velocities were recorded, then the ratio of E/A will be calculated.
3. IVRT (isovolumic relaxation time) - derived by placing the cursor of Continuous wave (CW) Doppler in the LV outflow tract to simultaneously display the end of aortic ejection and the onset of mitral inflow.
4. Deceleration time (DT) - from the peak of E wave to baseline.
5. E/e'- PW tissue Doppler imaging (TDI) was performed in the apical views to acquire mitral annular velocities. The sample volume will be positioned at or 1 cm within the mitral leaflet's septal and lateral insertion sites.
6. Left atrial volume and left atrial volume index (LAVI) - The maximal left atrial (LA) volume measured from the apical four-chamber view using the modified Simpson method in end-systole before mitral valve opening. The LAVI obtained for all patients by dividing the LA volume by the body surface area.

Biochemical measurements:

Peripheral blood samples were obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level.

Follow up 2D Doppler echocardiography:

All previous echocardiographic measurements will be repeated at 40 days of the event.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

STEMI - ST Elevation Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

STEMI patients who underwent PPCI

2D Echocardiography with color Doppler assessment will be done within 24 h after PPCI

Biochemical measurements:

Peripheral blood samples were obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level.

Follow up 2D Doppler echocardiography will be repeated at 40 days of the event.

2D Echocardiography with color Doppler assessment & Galactin-3 level in blood

Intervention Type DIAGNOSTIC_TEST

* Measurements will be

1. Pulsed wave (PW) Doppler
2. E (early diastolic)/A (late diastolic) - Using PW Doppler
3. IVRT (isovolumic relaxation time)
4. Deceleration time (DT) - from the peak of E wave to baseline.
5. E/e'- PW tissue Doppler imaging (TDI)
6. Left atrial volume and left atrial volume index (LAVI)
* Peripheral blood samples will be obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

2D Echocardiography with color Doppler assessment & Galactin-3 level in blood

* Measurements will be

1. Pulsed wave (PW) Doppler
2. E (early diastolic)/A (late diastolic) - Using PW Doppler
3. IVRT (isovolumic relaxation time)
4. Deceleration time (DT) - from the peak of E wave to baseline.
5. E/e'- PW tissue Doppler imaging (TDI)
6. Left atrial volume and left atrial volume index (LAVI)
* Peripheral blood samples will be obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients of sample size admitted to the cardiology department of Assiut university hospital with:

1. Acute typical chest pain
2. Positive cardiac enzymes.
3. ECG shows ST-segment elevation MI
4. Documented occlusion of CA then treatment by PPCI

Exclusion Criteria

* 1\. Patients with well-known factors of left ventricular diastolic dysfunctions, including high blood pressure (over 140/90 mmHg), hypertrophic cardiomyopathy, left ventricular hypertrophy, bundle branch block, ventricular fibrillation, ventricular arrhythmia, severe valvular disease, complete heart block, and previous CABG.

2\. Patients with the end-stage renal disease usually have markedly increased galactin-3 levels 3. Prior use of thrombolytic agents 4. Refusal of PPCI due to social or religious concerns 5. ST elevation on ECG without obvious coronary artery diseases such as acute myocarditis, early repolarization, or Takotsubo cardiomyopathy 6. Atrial fibrillation at the time of echocardiography examination.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mariam Bady Adly Hanna

Mariam Bady Adly Hanna

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hatem Helmy, Professor

Role: PRINCIPAL_INVESTIGATOR

Assiut University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Medicine Assiut University

Asyut, Asyut Governorate, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mariam Hanna, Resident

Role: CONTACT

Phone: +201069862210

Email: [email protected]

Yousra Ghazally, Lecturer

Role: CONTACT

Phone: +201003314748

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mariam Hanna

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Karaye KM, Sani MU. Factors associated with poor prognosis among patients admitted with heart failure in a Nigerian tertiary medical centre: a cross-sectional study. BMC Cardiovasc Disord. 2008 Jul 22;8:16. doi: 10.1186/1471-2261-8-16.

Reference Type BACKGROUND
PMID: 18644161 (View on PubMed)

McManus DD, Chinali M, Saczynski JS, Gore JM, Yarzebski J, Spencer FA, Lessard D, Goldberg RJ. 30-year trends in heart failure in patients hospitalized with acute myocardial infarction. Am J Cardiol. 2011 Feb 1;107(3):353-9. doi: 10.1016/j.amjcard.2010.09.026.

Reference Type BACKGROUND
PMID: 21256998 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PPCI in STEMI patients

Identifier Type: -

Identifier Source: org_study_id